| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Ro 363 is a potent and selective beta 1-adrenoceptor agonist and an effective inotropic stimulant, as well as a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility.
| ln Vitro |
Arrhythmic contractions were observed in isolated perfused cardiac preparations of guinea pigs following the administration of Ro 363 at dosages that reached 70–100% of their maximum chronotropic response [1]. In guinea pigs, RO 363 is a full agonist that has about half the potency of (-)-isoproterenol when it comes to inducing spontaneous tracheal contractions. Since RO 363 and (-)-isoproterenol have the same relative potency in tracheal, cardiac, and ileal preparations, these actions of RO 363 are caused by activation of a population of β1 receptors in tissues [2].
|
|---|---|
| ln Vivo |
Ro 363 has very minimal arrhythmogenic effect in cats under chloralose anesthesia when compared to epinephrine (epinephrine) in animals whose hearts have been sensitized by halothane or U-0882 [1].
|
| References |
[1]. Maccarrone C, et al. Comparison of the Arrhythmogenic Actions of (-)-Isoprenaline, Dobutamine and the selective beta 1-adrenoceptor agonist, (+/-)-(1-[3',4'-dihydroxyphenoxy] -2-hydroxy-[3",4"-dimethoxy phenethylamino]-propane)-oxalate (Ro 363). Arzneimit
[2]. Iakovidis D, et al. In vitro activity of RO363, a beta1-adrenoceptor selective agonist. Br J Pharmacol. 1980 Apr;68(4):677-85. [3]. Einstein R, et al. Comparison of the cardiac effects of beta-adrenoreceptor agonists in anaesthetised and conscious dogs. J Auton Pharmacol. 1986 Mar;6(1):9-14. |
| Exact Mass |
363.168
|
|---|---|
| CAS # |
74513-77-2
|
| Related CAS # |
74513-77-2;
|
| PubChem CID |
156297
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.245g/cm3
|
| Boiling Point |
600.3ºC at 760 mmHg
|
| Flash Point |
316.8ºC
|
| Index of Refraction |
1.587
|
| LogP |
2.077
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
26
|
| Complexity |
385
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
RFNBEBPVKCJZPV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H25NO6/c1-24-18-6-3-13(9-19(18)25-2)7-8-20-11-14(21)12-26-15-4-5-16(22)17(23)10-15/h3-6,9-10,14,20-23H,7-8,11-12H2,1-2H3
|
| Chemical Name |
1,2-Benzenediol, 4-(3-((2-(3,4-dimethoxyphenyl)ethyl)amino)-2-hydroxypropoxy)-, (+-)-
|
| Synonyms |
Ro363 Ro-363Ro 363
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06493799 | NOT YET RECRUITING | Drug: LAENNEC (Human Placenta Hydrolysate) IV Drug: LAENNEC (Human Placenta Hydrolysate) SC |
Chronic Liver Disease | Green Cross Wellbeing | 2024-07-01 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA